Abstract
Background: Hemoglobin (Hb) A(1c), a biochemical marker widely used in monitoring diabetes mellitus, can be quantitatively measured by various examining systems. However, significant errors still exist. In the present study, we evaluated the HbA(1c) level in five patients with compound heterozygotes by five different examining systems and our goal is to identify the existence of erroneous HbA(1c) measurement.Methods: Blood samples collected from normal (no hemoglobin variants) and abnormal (compound heterozygotes) patients were analyzed by capillary electrophoresis technique and sequence analysis. The samples without HbA expression via above methods were further analyzed for HbA(1c) by ion exchange HPLC Variant II/ Variant II Turbo 2.0 (VII and VII-T 2.0), boronate affinity HPLC, capillary electrophoresis, and Tinaquant immunoassay.Results: HbA(1c) expression were unexpectedly detected in the compound heterozygous samples by using additional examining systems: The HPLC VII and VII-T 2.0 detected HbA(1c) expression in two of five samples and failed to detect the abnormal HbA(2) expression; the CE system detected HbA(1c) expression in one of five samples with abnormal HbA(2) expression; the Ultra2 and PPI system detected the HbA(1c) expression of all samples without abnormal HbA(2)Conclusions: Five human samples without HbA expression were additionally detected with HbA(1c) expression with or without abnormal HbA(2) expression by five analysis systems and the different examining assay potentially affected the test results. These results demonstrated that the limitations of current examining systems for monitoring patients with hemoglobin disorders highlighting the further improvement in the method of clinical HbA examination.